-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4

Benzinga·08/14/2026 16:35:40
Listen to the news
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.